Search results for "ACETATE"

showing 10 items of 756 documents

Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics.

2009

X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder caused by mutations in the ABCD1 (ALD) gene. The ABCD2 gene, its closest homolog, has been shown to compensate for ABCD1 deficiency when overexpressed. We previously demonstrated that the ABCD2 promoter contains a functional thyroid hormone response element. Thyroid hormone (T3) through its receptor TRbeta can induce hepatic Abcd2 expression in rodents and transiently normalize the VLCFA level in fibroblasts of Abcd1 null mice. In a therapeutic perspective, the use of selective agonists of TRbeta should present the advantage to be devoid of side effects, at least concerning the cardiotoxicity associated to TRalpha activation. I…

medicine.medical_specialtyThyroid HormonesEndocrinology Diabetes and MetabolismClinical BiochemistryBiologyAcetatesATP Binding Cassette Transporter Subfamily DTransfectionBiochemistryEndocrinologyDownregulation and upregulationPhenolsInternal medicinePeroxisomal disorderGene expressionChlorocebus aethiopsmedicineAnimalsHumansReceptorAdrenoleukodystrophyMolecular BiologyHormone response elementReporter geneGlyoxylatesCell BiologyTransfectionmedicine.diseaseCell biologyRatsUp-RegulationEndocrinologyCOS CellsMolecular MedicineTriiodothyronineAdrenoleukodystrophyATP-Binding Cassette TransportersThe Journal of steroid biochemistry and molecular biology
researchProduct

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct

Progestogens stimulate prostacyclin production by human endothelial cells.

2005

BACKGROUND: The effects of progestogens on endothelial physiology are poorly studied. Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase (COX) in endothelium. We examined the effects of two clinically used progestogens, progesterone and medroxyprogesterone acetate (MPA), on prostacyclin production by cultured human umbilical vein endothelial cells (HUVEC) and the possible role of progesterone receptors and both COX enzymes. METHODS: Cells were exposed to 1-100 nmol/l of either progesterone or MPA and prostacyclin production was measured in culture medium. RESULTS: Both progestogens significantly increased prostacyclin release in a time- and dose-dependent man…

medicine.medical_specialtyUmbilical VeinsEndotheliumProstacyclinMedroxyprogesterone AcetateUmbilical veinInternal medicineProgesterone receptormedicineMedroxyprogesterone acetateHumansCyclooxygenase InhibitorsReceptorCells CulturedNitrobenzenesProgesteroneSulfonamidesbiologyCyclooxygenase 2 InhibitorsDose-Response Relationship DrugEstradiolRehabilitationObstetrics and GynecologyEndothelial CellsMembrane ProteinsEpoprostenolEndothelial stem cellMifepristoneEndocrinologymedicine.anatomical_structureReproductive MedicineCyclooxygenase 2Prostaglandin-Endoperoxide Synthasescardiovascular systembiology.proteinCyclooxygenase 1PyrazolesCyclooxygenaseEndothelium VascularProgestinsReceptors Progesteronemedicine.drugHuman reproduction (Oxford, England)
researchProduct

Effects of retinotoxic drugs on rats heterozygotic for recessive retinitis pigmentosa

1971

medicine.medical_specialtybusiness.industryIodoacetatesRats Inbred Strainsmedicine.diseaseRetinaSensory SystemsRatsFluoridesOphthalmologyEndocrinologyInternal medicineInjections IntravenousRetinitis pigmentosaElectroretinographymedicineAnimalsCholinesterasesbusinessRetinitis PigmentosaVision Research
researchProduct

Evolving European guidance on the medical management of neovascular age related macular degeneration

2006

BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. METHODS: Consensus from a round table of European retina specialists was obt…

medicine.medical_specialtygenetic structuresBevacizumabAntibodies Monoclonal HumanizedTriamcinolone AcetonideMacular DegenerationCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansPregnadienediolsEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryAntibodies MonoclonalAptamers NucleotideMacular degenerationFluorescein angiographymedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesSensory SystemsOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyPerspectivesense organsAnecortave acetateChoroidRanibizumabmedicine.symptombusinessmedicine.drugBritish Journal of Ophthalmology
researchProduct

Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal ho…

1999

Abstract Objective: To compare compliance, symptom control, bleeding patterns, endometrial response, and lipid changes in postmenopausal women treated with transdermal E 2 and a regimen of either intermittent or continuous dosing of progestin. Design: Randomized, prospective study. Setting: Menopausal Outpatient Clinic at an academic tertiary care hospital. Patient(s): One hundred women who had reached menopause naturally and had been amenorrheic for at least 1 year. Fifty women were randomly assigned to receive each regimen. Intervention(s): All patients received 50-μg E 2 patches and medroxyprogesterone acetate, either 5 mg twice per week or 2.5 mg daily. The bleeding pattern was register…

medicine.medical_specialtymedicine.drug_classMedroxyprogesteroneMedroxyprogesterone AcetateAdministration CutaneousEndometriumInternal medicinemedicineMedroxyprogesterone acetateOutpatient clinicHumansProspective StudiesProspective cohort studyAgedmedicine.diagnostic_testEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle Agedmedicine.diseaseLipidsSurgeryMenstruationMenopauseRegimenReproductive MedicinePatient ComplianceFemaleProgestinsbusinessProgestinmedicine.drugEndometrial biopsyFertility and sterility
researchProduct

A comparison of the relative efficacy of antiandrogens for the treatment of acne in hyperandrogenic women

2002

Summary objectives To compare the relative effectiveness of two newer antiandrogens (flutamide and finasteride) with cyproterone acetate (CPA), at both low and high doses in the treatment of moderate to severe acne in hyperandrogenic women. subjects and design Forty-eight hyperandrogenic women were prospectively randomized to the following treatments for 1 year: CPA 2 mg with 35 µg ethinylestradiol; CPA 50 mg with 25 µg ethinylestradiol (reverse sequential regimen); flutamide 250 mg daily; and finasteride 5 mg daily. Assessment of Cook scores was the primary end-point of the trial. Blood for androgens was obtained at baseline in these women and 30 ovulatory age-matched controls. results Ser…

medicine.medical_specialtymedicine.drug_classbusiness.industryEndocrinology Diabetes and MetabolismHyperandrogenismCyproterone acetateAntiandrogenmedicine.diseaseFlutamidechemistry.chemical_compoundEndocrinologyEndocrinologychemistryEthinylestradiolInternal medicineFinasteridemedicineCyproteronebusinessAcnemedicine.drugClinical Endocrinology
researchProduct

Anti-inflammatory effects of zinc in PMA-treated human gingival fibroblast cells

2015

Objectives: Abnormal cellular immune response has been considered to be responsible for oral lesions in recurrent aphthous stomatitis. Zinc has been known to be an essential nutrient metal that is necessary for a broad range of biological activities including antioxidant, immune mediator, and anti-inflammatory drugs in oral mucosal disease. The objective of this study was to investigate the effects of zinc in a phorbol-12-myristate-13-acetate (PMA)-treated inflammatory model on human gingival fibroblast cells (hGFs). Study Design: Cells were pre-treated with zinc chloride, followed by PMA in hGFs. The effects were assessed on cell viability, cyclooxygenease-1,2(COX-1/2) protein expression, …

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentGingivachemistry.chemical_elementOdontologíaInflammationZincPharmacologyRecurrent aphthous stomatitisAnti-inflammatoryImmune systemInternal medicinemedicineHumansViability assayGeneral DentistryCells CulturedInflammationOral Medicine and PathologyChemistryResearchFibroblasts:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludZincCytokineEndocrinologyOtorhinolaryngologyTetradecanoylphorbol AcetateUNESCO::CIENCIAS MÉDICASCytokinesTetradecanoylphorbol AcetateSurgerymedicine.symptomMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

HDlive imaging of cystic uterine leiomyoma degeneration

2016

medicine.medical_specialtymedicine.medical_treatmentTreatment outcomeDegeneration (medical)03 medical and health scienceschemistry.chemical_compound0302 clinical medicineUlipristal acetatemedicineRadiology Nuclear Medicine and imaging030212 general & internal medicine030219 obstetrics & reproductive medicineHysterectomyUterine leiomyomaRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryObstetrics and GynecologyMagnetic resonance imagingGeneral Medicinemedicine.diseaseLeiomyomaReproductive MedicinechemistryRadiologyUltrasonographybusinessUltrasound in Obstetrics & Gynecology
researchProduct

Progestogens and risk of breast cancer: a link between bone and breast?

2015

This article reviews the data supporting the role of receptor activator of the nuclear factor kappa (RANK) and its ligand, RANKL, in progestogen-induced breast cancer. Both experimental and clinical studies have been included. The expression of both RANK and RANKL has been described in epithelial cells of both mice and humans. Experiments of gain and loss of function in mice have shown that RANK/RANKL mediate alveologenesis during pregnancy or the estrous cycle. Moreover, the participation of the RANK/RANKL has been detected in models of breast carcinogenesis associated with progestogens-like medroxyprogesterone acetate. Recent clinical studies have found that the expression of RANK is asso…

musculoskeletal diseases0301 basic medicineEndocrinology Diabetes and MetabolismOsteoclastsBone NeoplasmsBreast NeoplasmsMice03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerRisk FactorsmedicineAnimalsHumansMedroxyprogesterone acetateBreastReceptorProgesteroneLoss functionEstrous cyclePregnancyReceptor Activator of Nuclear Factor-kappa BbiologyActivator (genetics)business.industryRANK LigandObstetrics and Gynecologymedicine.disease030104 developmental biologyRANKL030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchFemaleProgestinsbusinessmedicine.drugGynecological Endocrinology
researchProduct